GlucoSiFA and LactoSiFA: New Types of Carbohydrate-Tagged Silicon-Based Fluoride Acceptors for ¹⁸F-Positron Emission Tomography (PET)

Published as part of the 50 Years SYNTHESIS – Golden Anniversary Issue

Key words

carbohydrates - silicon-based fluoride acceptors - nucleo­philic substitution - tosylation - regioselectivity

The introduction of positron emission tomography (PET) as a non-invasive method for medical diagnostic in vivo imaging has become an indispensable tool in precision medicine development.[1] PET not only helps to understand the complex interplay between biological targets such as receptors and enzymes and their cognate ligands but furthermore assists devising new therapeutic regimens based on non-invasive biological target validation. Besides PET, a straightforward example for diagnostic imaging is the use of X-rays that has revolutionized medicine. However, this method only yields anatomic/structural information whereas PET and related radioisotope-based imaging methodologies look directly at dynamic biological processes without interference. PET, in addition to magnetic resonance imaging (MRI) and computed tomography (CT), has proved to be an elegant and non-invasive method to elucidate in vivo biochemistry. It allows metabolic tracking of bioactive compounds and quantification of biochemical and/or enzymatic processes in living organisms. Among commonly used radioactive isotopes such as ¹¹C, ¹³N, ¹⁵O, ¹⁸F, ⁶⁴Cu, and ⁶⁸Ga,[2] the use of fluorine-18 has become rather popular due to its favorable physical properties such as a half-life of 109.7 minutes that allows for longer synthesis times and remote shipment to local imaging facilities and a low positron energy leading to PET images of highest resolution.

There are different strategies for incorporating ¹⁸F into radiopharmaceuticals. On the one hand, fluorination at carbon atoms in both aromatic and aliphatic compounds can be achieved by electrophilic as well as nucleophilic reactions and a variety of appropriate reagents has been developed for this purpose.[2] [3] Alternatively, ¹⁸F can also be bound via isotopic exchange to non-carbon elements such as ­boron, aluminum, silicon, and phosphorus.[3a] These non-­canonical labeling concepts got momentum in the last two decades although some of the labeling principles have already been introduced to the literature as early as 1958[4] but remained dormant for many years. The progress achieved in these types of chemistry was regularly summarized in review articles.[3a] [5] Aryldialkylsilicon fluorides, ArR₂SiF, in which the silicon atom is sufficiently protected with R = isopropyl[6] or tert-butyl[7a] substituents are stable under physiological conditions and undergo ¹⁹F to ¹⁸F isotopic ­exchange with good radiochemical yields. The tert-butyl-substituted variant is now widely known as SiFA methodology and has become popular in several research groups (Equation 1).[7b] [c] [d] [e]

Equation 1 Isotope exchange in silicon-based fluoride acceptors (SiFA)

One last problem when using SiFA-substituted biomolecules for PET applications is the high lipophilicity caused by the organosilicon moiety. Sugars such as glucose are water-soluble and carbon-bound ¹⁸F-derivatives such a 2-[¹⁸F]fluo­rodeoxyglucose ([¹⁸F]FDG) are applied as PET radiotracers.[7e] [f] With this in mind and the intention to increase the water-solubility of the SiFA moiety, herein we report the synthesis and characterization of SiFA-substituted sugar derivatives that also contain a variety of functional groups that hold potential for subsequent protein conjugation by click-type chemistry.

Our synthesis of the β-d-azido-substituted GlucoSiFA derivative 5 (Scheme [1]) started with peracetyl-d-glucose (1; mixture of anomers), which was first brominated at the anomeric center with HBr/AcOH. The resulting α-d-glycosyl bromide underwent clean substitution with sodium azide to afford β-d-glycosyl azide 2. Both steps proceeded in excellent yield, as did the subsequent deprotection with sodium methoxide. A selective monotosylation at the primary hydroxy group of the unprotected β-d-azidoglucose gave the difunctionalized monosaccharide 3 in 72% yield. Finally, the desired GlucoSiFA derivative 5 was obtained in 74% yield (51% over 5 steps) by nucleophilic substitution of the tosylate with deprotonated 4-(di-tert-butylfluorsilyl)benzenethiol (4).[8] Due to the pronounced base sensitivity of SiFA derivatives, this step has to be carried out with bulky, less nucleophilic bases. In the event, potassium tert-butoxide in DMSO gave the best results.

Scheme 1 Synthesis of β-d-azido-substituted GlucoSiFA derivative 5

Starting point of the synthesis of the β-d-alkynyl-substituted GlucoSiFA derivative 8 (Scheme [2]) was the Lewis acid catalyzed substitution of the anomeric acetyl group of peracetyl-d-glucose (1) with propargyl alcohol, which provided β-d-glycoside 6 in 76% yield. The following steps via monotosylate 7 proceeded as before and gave target molecule 8 in 33% yield over four steps.

Scheme 2 Synthesis of β-d-alkynyl-substituted GlucoSiFA derivative 8

In order to further increase the hydrophilicity of carbohydrate-tagged SiFA derivatives, we next used disaccharides as starting material. Here, serious reactivity and selectivity issues were encountered. For example, even though β-d-azidogalactose can be monotosylated selectively at the primary hydroxy group, all attempts of a monotosylation of β-d-azidomelibiose (which also contains only one primary hydroxy group) failed and provided either mixtures of bistosylated products at low yield, or no product at all. We then shifted our attention to maltose and lactose as starting disaccharides and first prepared two-fold SiFA-substituted derivatives (Scheme [3]).

Scheme 3 Synthesis of two-fold SiFA-substituted maltose and lactose derivatives 11 and 14

Whereas the tosylation of β-azido-d-maltose (9a) with pTsCl in pyridine proceeded rather sluggishly, the reactivity was strongly increased in the presence of zinc bromide.[9] Under these conditions, complete conversion was observed after 1 hour at –20 °C, and the bistosylate 10a was isolated in 50% yield. Both leaving groups could be replaced with SiFA moieties under standard conditions using 4 and tBuOK to afford the target molecule 11a in 67% yield. The corresponding SiFA-tagged β-alkynyl-d-maltose 11b was obtained in the same manner from 9b via bistosylate 10b in 31% and 55% yield, respectively.

Similar to the maltose derivatives, the corresponding β-azido- and alkynyl-substituted d-lactoses 12a/b could not be selectively monotosylated at one of the two primary hydroxy groups. Rather, the bistosylates 13a/b were obtained in 44% and 36% yield, which were converted into the two-fold SiFA-modified lactoses 14a/b in moderate yields (33/36%).

It is evident from these results that a protection of one of the two primary hydroxy groups is required for the synthesis of a disaccharide bearing only one SiFA unit. Gratifyingly, the presence of an axial OH group in the galactose ring of β-d-azidolactose 12a allows a selective acetalization to afford product 15 in 74% yield (Scheme [4]).[10] For this substrate, the selectivity of the tosylation was examined in detail (Table [1]).

Scheme 4 Synthesis of β-d-azido-substituted LactoSiFA derivative 19

With 4 equivalents of zinc bromide and 5 equivalents of tosyl chloride in pyridine at –20 °C, a mixture of the desired monotosylate 16 (41% yield) and the bistosylate 17 (21% yield) was obtained after 10 minutes (Table [1], entry 1). Thus, not only the primary, but also the secondary hydroxy group at C-4′ are reactive under these conditions. As expected, increasing the reaction time up to 40 minutes favored the formation of the bistosylate 17 (entries 2–4); the best yield of the monotosylate 16 (49%) was obtained after 30 minutes and decreased to 30% after 40 minutes. Smaller amounts of pTsCl afforded a higher selectivity in favor of the monotosylate 16 (entries 5 and 6), which was isolated as the sole product in the presence of 1.3 equivalents of pTsCl (entry 6), albeit in a low yield of 30%. Interestingly, the tosylation of the corresponding lactose derivative bearing a propargyl glycoside instead of the azido group gave only a bistosylate bearing the tosyl groups at the 2-CH₂ group and C-4. At this point, it is not clear which factors govern the regioselectivity of these transformations. Unfortunately, attempts to introduce other leaving groups (mesylate, 4-bromophenylsulfonate, bromide) failed.

The structural assignment of tosylation products 16 and 17 is based on extensive NMR studies. Moreover, both products were isolated in crystalline form and characterized by single crystal X-ray diffraction analysis. The quality of the crystals of monotosylate 16 was rather low and allowed only the structural assignment of the constitution, but not of the absolute stereochemistry of the acetal stereocenter. In contrast to this, the acetal stereocenter of the major isomer (87%) of bistosylate 17 (Figure [1]) shows S-configuration as estimated by the twin law of the measured crystal.[11] The X-ray diffraction analysis also proved the presence of the two tosyl groups at the 2-CH₂ and 4′ positions.

Table 1 Tosylation of Disaccharide 15 ^a

Entry	ZnBr2·2 H2O (equiv)	pTsCl (equiv)	Time (min)	16 (Yield %)	17 (Yield %)
1	4	5	10	41	21
2	4	5	20	38	30
3	4	5	30	49	31
4	4	5	40	30	34
5	1.5	2	40	39	24
6	4	1.3	40	30	0

^a In pyridine at –20 °C.

Figure 1 X-ray crystal structure of bistosylate 17

The protected monotosylated β-azido-d-lactose derivative 16 obtained in 49% yield under the conditions of Table [1], entry 3, was treated with the thiolate formed by deprotonation of 4-(di-tert-butylfluorsilyl)benzenethiol (4) with tBuOK. The SiFA-tagged lactose derivative 18 was isolated in 61% yield. Finally, acetal cleavage was achieved by heating 18 with 80% aqueous acetic acid to 70 °C for 4 hours. This afforded the desired β-d-azido-substituted LactoSiFA derivative 19 in 64% yield (14% over 4 steps from 12a) (Scheme [4]).

In conclusion, this work demonstrates the utility of carbohydrates for the synthesis of hydrophilic SiFA derivatives. The GlucoSiFA derivatives 5 and 8 bearing an azide or alkynyl handle for peptide and protein conjugation via 1,3-dipolar cycloaddition were obtained in a straightforward manner from peracetyl-d-glucose in 51% and 36% overall yield, respectively. The key step is the substitution of a tosylate by a SiFA thiolate obtained from 4-(di-tert-butylfluorsilyl)benzenethiol (4). In analogy, the two-fold SiFA-substituted maltose and lactose derivatives 11 and 14 are readily accessible in overall yields between 13% and 34%. Introduction of an acetal protecting group in β-d-azidolactose 12a allowed the synthesis of the LactoSiFA derivative 19 in 14% overall yield. Further work is devoted to improved procedures for the monofunctionalization of suitable carbohydrates, as well as, the synthesis of carbohydrate-tagged SiFA derivatives bearing different handles for protein conjugation.

Reactions were carried out under argon atmosphere using oven- or flame-dried glassware. Air- and moisture-sensitive reagents were transferred via syringe. All reagents were obtained commercially and used without further purification. THF, Et₂O, CH₂Cl₂, and MeCN were dried using a MB-SPS-800 system (M. Braun). Reactions were monitored by TLC using silica gel 60 plates provided by Merck and ­Macherey-Nagel. Visualization was accomplished with UV light (254 nm), ceric ammonium molybdate, KMnO₄, or anisaldehyde.

¹H, ¹³C, ¹⁹F, and ²⁹Si NMR spectra were recorded with Bruker Avance III HD (400–600 MHz) and calibrated against residual solvent peaks. IR spectra were obtained with a PerkinElmer Spectrum Two UATR spectrophotometer. Mass spectra were recorded with a Thermo Fisher Scientific TSQ (LCMS-ESI) and a Thermo Electron LTQ Orbitrap spectrometer (HPLC-ESI).

(3R,4S,5R,6R)-6-(Acetoxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrayltetraacetate (1),[12] (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-bromo­tetrahydro-2H-pyran-3,4,5-triyltriacetate,[13] (2R,3R,4S,5R,6R)-2-(acet­oxymethyl)-6-azidotetrahydro-2H-pyran-3,4,5-triyltriacetate (2),[14] (2R,3R,4S,5S,6R)-2-azido-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol,[15] (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-3,4,5-triyltriacetate (6),[16] (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(prop-2-yn-1-yloxy)tetra­hydro-2H-pyran-3,4,5-triol,[17] (2S,3R,4S,5R,6R)-6-(acetoxymethyl)-5-{[(2R,3R,4S,5R,6R)-3,4,5-triacetoxy-6-(acetoxymethyl)-tetrahydro-2H-pyran-2-yl]oxy}tetrahydro-2H-pyran-2,3,4-triyltriacetate,[18] (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-{[(2R,3R,4S,5R,6R)-4,5-diacet­oxy-2-(acetoxymethyl)-6-bromotetrahydro-2H-pyran-3-yl]oxy}tetra­hydro-2H-pyran-3,4,5-triyltriacetate,[19] (2R,3R,4S,5R,6R)-2-(acet­oxymethyl)-6-{[(2R,3R,4S,5R,6R)-4,5-diacetoxy-2-(acetoxymethyl)-6-azidotetrahydro-2H-pyran-3-yl]oxy}tetrahydro-2H-pyran-3,4,5-triyltriacetate,[20] (2R,3R,4S,5S,6R)-2-{[(2R,3S,4R,5R,6R)-6-azido-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (9a),[21] (2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-{[(2R,3R,4S,5R,6R)-4,5-diacet­oxy-2-(acetoxymethyl)-6-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-3-yl]oxy}tetrahydro-2H-pyran-3,4,5-triyltriacetate,[22] (2R,3R,4S,5S,6R)-2-{[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymeth­yl)-6-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-3-yl]oxy}-6-(hydroxy­methyl)tetrahydro-2H-pyran-3,4,5-triol (9b),[23] (3R,4S,5R,6R)-6-(acet­oxymethyl)-5-{[(2S,3R,4S,5S,6R)-3,4,5-triacetoxy-6-(acetoxymethyl)-tetrahydro-2H-pyran-2-yl]oxy}tetrahydro-2H-pyran-2,3,4-triyltriacetate,[24] (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-{[(2R,3R,4S,5R,6R)-4,5-diacetoxy-2-(acetoxymethyl)-6-bromtetrahydro-2H-pyran-3-yl]oxy}-tetrahydro-2H-pyran-3,4,5-triyltriacetate,[19] (2R,3S,4S,5R,6S)-2-(acet­oxymethyl)-6-{[(2R,3R,4S,5R,6R)-4,5-diacetoxy-2-(acetoxymethyl)-6-azidotetrahydro-2H-pyran-3-yl]oxy}tetrahydro-2H-pyran-3,4,5-triyltriacetate,[20] (2S,3R,4S,5R,6R)-2-{[(2R,3S,4R,5R,6R)-6-azido-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (12a),[25] (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-{[(2R,3R,4S,5R,6R)-4,5-diacet­oxy-2-(acetoxymethyl)-6-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-3-yl]oxy}tetrahydro-2H-pyran-3,4,5-triyltriacetate,[26] (2S,3R,4S,5R,6R)-2-{[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymeth­yl)-6-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-3-yl]oxy}-6-(hydroxy­methyl)tetrahydro-2H-pyran-3,4,5-triol (12b),[26] and (4aR,6S,7R,8R)-6-{[(2R,3S,4R,5R,6R)-6-azido-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]oxy}-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7,8-diol (15)[10] are known compounds and were prepared according to literature procedures.

[(2R,3S,4S,5R,6R)-6-Azido-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl]methyl 4-Methylbenzolsulfonate (3)

A solution of (2R,3R,4S,5S,6R)-2-azido-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (585 mg, 2.85 mmol, 1.0 equiv) in anhyd pyridine (6 mL) was cooled to 0 °C and treated with pTsCl (706 mg, 3.71 mmol, 1.3 equiv) in anhyd pyridine (3 mL). The mixture was stirred at rt for 24 h. The solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel, EtOAc); yield: 742 mg (72%); colorless solid.

IR (ATR): 3354, 3290, 2115, 1347, 1248, 1188, 1167, 1106, 1079, 1057, 1012, 967, 894, 813, 781, 705, 663, 552, 505 cm^–1.

¹H NMR (600 MHz, DMSO-d ₆): δ = 7.78 (d, J = 8.3 Hz, 2 H, ArH), 7.48 (d, J = 8.2 Hz, 2 H, ArH), 5.57 (d, J = 5.6 Hz, 1 H, CHOH), 5.34 (d, J = 5.7 Hz, 1 H, CHOH), 5.23 (d, J = 5.3 Hz, 1 H, CHOH), 4.51 (d, J = 8.7 Hz, 1 H, β-H₁), 4.24 (dd, J ₁ = 10.8 Hz, J ₂ = 1.7 Hz, 1 H), 3.52 (ddd, J ₁ = 9.8 Hz, J ₂ = 6.5 Hz, J ₃ = 1.7 Hz, 1 H), 3.16 (td, J ₁ = 8.9 Hz, J ₂ = 5.2 Hz, 1 H), 3.04 (td, J ₁ = 9.4 Hz, J ₂ = 5.6 Hz, 1 H), 2.95 (td, J ₁ = 8.8 Hz, J ₂ = 5.6 Hz, 1 H), 2.43 (s, 3 H, ArCH ₃).

¹³C NMR (150 MHz, DMSO-d ₆): δ = 132.6 (s, ipso-Ar), 130.6, 128.1 (2 d, Ar), 90.1 (d, CHN₃), 76.5 (d, CHCH₂), 75.7, 73.5, 70.3 (3 d, CHOH), 69.5 (t, CH₂OH), 21.6 (q, ArCH₃).

4-(Di-tert-butylfluorsilyl)benzenethiol (4)

The procedure published previously[8] was improved as follows. A solution of tBuLi in pentane (8.05 mL, 1.9 M, 15.3 mmol, 2.0 equiv) was added dropwise under magnetic stirring to a –78 °C cold solution of (4-bromophenylsulfanyl)-tert-butyldimethylsilane (2.32 g, 7.65 mmol, 1.0 equiv) in Et₂O (50 mL). After stirring the reaction mixture for 25 min at –78 °C, di-tert-butyldifluorosilane (1.52 g, 8.41 mmol, 1.1 equiv) was added dropwise. The reaction mixture was allowed to warm up to rt over a period of 24 h and brine (50 mL) was added. The organic layer was separated, and the aqueous layer was extracted with Et₂O (4 × 50 mL). The combined organic layers were dried (MgSO₄). The filtrate was concentrated in vacuo to give 1-(tert-butyldimethylsilanylsulfanyl)-4-(di-tert-butylfluorosilanyl)benzene as a yellow oil that solidified (2.58 g, 6.70 mmol, 88%). The subsequent deprotection to afford 4 was carried out as described previously.[8]

(2R,3R,4S,5S,6S)-2-Azido-6-({[4-(di-tert-butylfluorosilyl)phenyl]thio}methyl)tetrahydro-2H-pyran-3,4,5-triol (5)

A solution of 4 (50 mg, 0.18 mmol, 1.2 equiv) in anhyd DMSO (1 mL) was treated with tBuOK (20 mg, 0.18 mmol, 1.2 equiv). The mixture was stirred at 50 °C for 30 min. After the addition of 3 (54 mg, 0.15 mmol, 1 equiv) in anhyd DMSO (1 mL), the mixture was stirred at 50 °C for 24 h. Cooling to rt was followed by addition of excess aq 1 M HCl. The mixture was dissolved to Et₂O and washed with aq 1 M HCl (3 × 20 mL) and H₂O (3 × 20 mL). After drying (MgSO₄), the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with pentane/Et₂O (15:1) and ending with Et₂O/MeOH (20:1); yield: 51.1 mg (74%); colorless powder.

IR (ATR): 3354 (br), 2933, 2859, 2117, 1582, 1471, 1386, 1365, 1245, 1064, 1011, 969, 936, 836, 824, 811, 740, 715, 646, 599 cm^–1.

¹H NMR (600 MHz, CDCl₃): δ = 7.52 (d, J = 8.1 Hz, 2 H, ArH), 7.39 (d, J = 8.1 Hz, 2 H, ArH), 4.59 (d, J = 8.4 Hz, 1 H, β-H₁), 3.69–3.66 (m, 1 H), 3.59–3.48 (m, 4 H), 3.34 (t, J = 8.5 Hz, 1 H), 3.31 (dd, J ₁ = 14.1 Hz, J ₂ = 7 Hz, 1 H), 1. 05 [s, 18 H, 2 × C(CH₃)₃].

¹³C NMR (150 MHz, CDCl₃): δ = 138.4 (s, Ar), 134.5 (d, J = 4.1 Hz, Ar), 130.8 (s, J = 13.8 Hz, Ar), 127.2 (d, Ar), 90.0 (d, CHN₃), 76.9, 76.4, 73.5, 72.5 (4 d, CH), 34.5 (t, CH₂S), 27.3 [q, C(CH₃)₃], 20.3 [s, J = 12.4 Hz, C(CH₃)₃].

¹⁹F NMR (565 MHz, CDCl₃): δ = –188.9 (d, J = 297.8 Hz).

²⁹Si NMR (119 MHz, CDCl₃): δ = 15.3 (d, J = 297.8 Hz).

HRMS (ESI): m/z calcd for C₂₀H₃₃FN₃O₄SSi [M + H]⁺: 458.19396; found: 458.19396.

[(2R,3S,4S,5R,6R)-3,4,5-Trihydroxy-6-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-2-yl]methyl 4-Methylbenzolsulfonate (7)

A solution of (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-3,4,5-triol (847 mg, 3.88 mmol, 1.0 equiv) in anhyd pyridine (7 mL) was cooled to 0 °C and treated with pTsCl (962 mg, 5.05 mmol, 1.3 equiv) in anhyd pyridine (3 mL). The mixture was stirred at rt for 24 h. The solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel, EtOAc); yield: 1.22 g (84%); colorless solid.

IR (ATR): 3325, 2899, 1596, 1446, 1356, 1188, 1176, 1080, 1046, 997, 925, 833, 814, 687, 656, 620, 550, 502 cm^–1.

¹H NMR (600 MHz, CD₃OD): δ = 7.81 (d, J = 8.3 Hz, 2 H, ArH), 7.45 (d, J = 8.1 Hz, 2 H, ArH), 4.37 (d, J = 7.8 Hz, 1 H, β-H₁), 4.34 (dd, J ₁ = 10.9 Hz, J ₂ = 1.8 Hz, 1 H), 4.29–4.26 (m, 1 H), 4.21 (s, 1 H), 4.19–4.15 (m, 1 H), 3.39 (ddd, J ₁ = 9.8 Hz, J ₂ = 5.9 Hz, J ₃ = 1.9 Hz, 1 H), 3.30–3.28 (m, 1 H), 3.22–3.19 (m, 1 H), 3.11 (dd, J ₁ = 9.2 Hz, J ₂ = 7.9 Hz, 1 H), 2.46 (s, 3 H, ArCH ₃). OH groups were not detected.

¹³C NMR (150 MHz, CD₃OD): δ = 146.7, 134.6 (2 s, Ar), 131.2, 129.3 (2 d, Ar), 102.1 (d, CHOCH₂), 80.0 (s, C≡C), 77.9 (d, CH), 76.5 (s, C≡C), 75.2, 74.8, 71.2 (2 d, CH), 70.8 (t, CH₂OTs), 56.7 (t, CH₂C≡C), 21.8 (ArCH₃).

HRMS (ESI): m/z calcd for C₁₆H₂₀O₈SNa [M + Na]⁺: 395.07711; found: 395.07671.

(2S,3S,4S,5R,6R)-2-({[4-(Di-tert-butylfluorosilyl)phenyl]thio}methyl)-6-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-3,4,5-triol (8)

A solution of 4 (50 mg, 0.18 mmol, 1.2 equiv) in anhyd DMSO (1 mL) was treated with tBuOK (20 mg, 0.18 mmol, 1.2 equiv). The mixture was stirred at 50 °C for 30 min. After the addition of 7 (56 mg, 0.15 mmol, 1 equiv) in anhyd DMSO (1 mL), the mixture was stirred at 50 °C for 24 h. Cooling to rt was followed by addition of excess aq 1 M HCl. The mixture was dissolved in Et₂O and washed with aq 1 M HCl (3 × 20 mL) and H₂O (3 × 20 mL). After drying (MgSO₄), the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with pentane/Et₂O (15:1) and ending with Et₂O/MeOH (20:1); yield: 36.8 mg (52%); colorless powder.

IR (ATR): 3347, 3293, 2934, 2859, 1582, 1470, 1387, 1365, 1262, 1180, 1066, 1007, 824, 811, 740, 716, 645 cm^–1.

¹H NMR (400 MHz, CDCl₃): δ = 7.57–7.49 (m, 2 H, ArH), 7.39–7.36 (m, 2 H, ArH), 4.50 (d, J = 7.3 Hz, 1 H, β-H₁), 4.36 (dd, J ₁ = 15.7 Hz, J ₂ = 2.4 Hz, 1 H), 4.25 (dd, J ₁ = 15.9 Hz, J ₂ = 2.2 Hz, 1 H), 3.61–3.48 (m, 4 H), 3.46–3.41 (m, 1 H), 3.17 (dd, J ₁ = 14.2 Hz, J ₂ = 7.3 Hz, 1 H), 2.48 (t, J = 2.4 Hz, 1 H), 1.60 (br s, 3 H, CHOH), 1. 05 [s, 18 H, 2 × C(CH₃)₃].

¹³C NMR (100 MHz, CDCl₃): δ = 138.8 (s, Ar), 134.4 (d, Ar), 130.4 (s, Ar), 127.1 (d, Ar), 100.1 (d, CHOCH₂), 77.2 (s, C≡C), 76.3 (d, CH), 75.4 (s, C≡C), 75.3, 73.6, 72.9 (3 d, CH), 55.9 (t, CH₂C≡C), 34.5 (t, CH₂S), 27.3 [q, C(CH₃)₃], 20.3 [s, J = 12.5 Hz, C(CH₃)₃].

¹⁹F NMR (565 MHz, CDCl₃): δ = –188.9 (d, J = 297.6 Hz).

²⁹Si NMR (119 MHz, CDCl₃): δ = 15.3 (d, J = 297.8 Hz).

HRMS (ESI): m/z calcd for C₂₃H₃₅FO₅SSiNa [M + Na]⁺: 493.18507; found: 493.18476.

((2R,3S,4S,5R,6R)-6-{[(2R,3S,4R,5R,6R)-6-Azido-4,5-dihydroxy-2-[(tosyloxy)methyl]tetrahydro-2H-pyran-3-yl]oxy}-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-Methylbenzenesulfonate (10a)

A solution of 9a (100 mg, 0.27 mmol, 1.0 equiv) in anhyd pyridine (2.4 mL) was cooled to –20 °C and treated with ZnBr₂·2 H₂O (243 mg, 1.08 mmol, 4.0 equiv) and then with pTsCl (257 mg, 1.35 mmol, 5.0 equiv) in anhyd pyridine (1 mL). The mixture was stirred at –20 °C for 1 h. The reaction was carried out three times in separate flasks. The reaction mixtures were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel, EtOAc); yield: 367 mg (50%); colorless solid.

IR (ATR): 3375, 2363, 2330, 2119, 1598, 1450, 1353, 1190, 1173, 1141, 1071, 973, 928, 812, 688, 660, 551, 502 cm^–1.

¹H NMR (500 MHz, CD₃OD): δ = 7.82–7.77 (m, 4 H, ArH), 7.44 (d, J = 7.1 Hz, 4 H, ArH), 4.97 (d, J = 3.7 Hz, 1 H, α-H_1′), 4.43 (d, J = 8.7 Hz, 1 H, β-H₁), 4.32–4.30 (m, 2 H), 4.19–4.16 (m, 2 H), 3.71–3.68 (m, 1 H), 3.63–3.60 (m, 1 H), 3.52 (m, 2 H), 3.36–3.33 (m, 1 H), 3.25 (t, J = 9.5 Hz, 1 H), 3.07 (t, J = 9 Hz, 1 H), 2.46 (d, J = 5.3 Hz, 6 H, ArCH ₃). OH groups were not detected.

¹³C NMR (125 MHz, CD₃OD): δ = 146.8, 146.6, 134.5, 134.4 (4 s, Ar), 131.3, 131.2, 129.4, 129.3 (4 d, Ar), 103.0 (d, CHO), 91.7 (d, CHN₃), 80.7, 77.6, 75.6, 74.9, 74.0, 73.8, 72.4, 70.7 (8 d), 70.5, 70.4 (2 t, CH₂OTs), 21.8 (q, ArCH₃).

HRMS (ESI): m/z calcd for C₂₆H₃₃N₃O₁₄S₂Na [M + Na]⁺: 698.12962; found: 698.12955.

(2S,3R,4S,5S,6S)-2-{[(2S,3S,4R,5R,6R)-6-Azido-2-({[4-(di-tert-butylfluorosilyl)phenyl]thio}methyl)-4,5-dihydroxytetrahydro-2H-pyran-3-yl]oxy}-6-({[4-(di-tert-butylfluorsilyl)phenyl]thio}methyl)tetrahydro-2H-pyran-3,4,5-triol (11a)

A solution of 4 (192.2 mg, 0.71 mmol, 2.4 equiv) in anhyd DMSO (3 mL) was treated with tBuOK (79.7 mg, 0.71 mmol, 2.4 equiv). The mixture was stirred at 50 °C for 30 min. After the addition of 10a (200 mg, 0.30 mmol, 1 equiv) in anhyd DMSO (1 mL), the mixture was stirred at 50 °C for 48 h. Cooling to rt was followed by addition of excess aq 1 M HCl. The mixture was dissolved in Et₂O and washed with aq 1 M HCl (3 × 20 mL) and H₂O (3 × 20 mL). After drying (MgSO₄), the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with cyclohexane/EtOAc (3:1) and ending with EtOAc/MeOH (10:1); yield: 174 mg (67%); colorless solid.

IR (ATR): 3325, 2934, 2859, 2117, 1715, 1582, 1470, 1373, 1250, 1056, 1012, 939, 816, 740, 645, 600, 504 cm^–1.

¹H NMR (600 MHz, DMSO-d ₆): δ = 7.42–7.36 (m, 6 H, ArH), 7.25 (d, J = 8 Hz, 2 H, ArH), 5.84–5.83 (m, 1 H), 5.75 (d, J = 6.3 Hz, 1 H), 5.66 (d, J = 5.5 Hz, 1 H), 5.32 (d, J = 5.8 Hz, 1 H), 5.13–5.08 (m, 2 H), 4.57 (d, J = 8.7 Hz, 1 H, β-H₁), 3.79 (t, J = 7.2 Hz, 1 H), 3.70–3.67 (m, 1 H), 3.56 (d, J = 12.3 Hz, 1 H), 3.49–3.41 (m, 3 H), 3.25–3.20 (m, 1 H), 3.16–3.11 (m, 1 H), 3.09–3.05 (m, 1 H), 3.03–3.00 (m, 1 H), 1.00–0.94 [m, 36 H, 4 × C(CH₃)₃].

¹³C NMR (150 MHz, DMSO-d ₆): δ = 140.0, 139.7 (2 s, Ar), 133.9 (d, J = 4.1 Hz, Ar), 133.8 (d, J = 3.9 Hz, Ar), 128.6 (s, J = 13.8 Hz, Ar), 128.4 (s, J = 13.8 Hz, Ar), 126.4, 125.9 (2 d, Ar), 101.4 (d, CHO), 89.6 (d, CHN₃), 82.6, 75.8, 75.5, 72.8, 72.7, 72.5, 72.3, 72.1 (8 d, CH), 59.7 (t, CH₂S), 39.0 (t, CH₂S), 28.0 [q, J = 6.1 Hz, C(CH₃)₃], 27.0 [q, J = 6.6 Hz, C(CH₃)₃], 19.8 [s, J = 12.4 Hz, C(CH₃)₃], 19.7 [s, J = 12.4 Hz, C(CH₃)₃].

¹⁹F NMR (565 MHz, DMSO-d ₆): δ = –187.5 (d, J = 297.8 Hz).

²⁹Si NMR (119 MHz, DMSO-d ₆): δ = 15.4 (d, J = 297.8 Hz).

HRMS (ESI): m/z calcd for C₄₀H₆₃F₂N₃O₈S₂Si₂Na [M + H + Na]⁺: 894.34609; found: 894.34644.

((2R,3S,4S,5R,6R)-6-{[(2R,3S,4R,5R,6R)-4,5-Dihydroxy-6-(prop-2-yn-1-yloxy)-2-[(tosyloxy)methyl]tetrahydro-2H-pyran-3-yl]oxy}-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-Methylbenzenesulfonate (10b)

A solution of 9b (100 mg, 0.26 mmol, 1.0 equiv) in anhyd pyridine (2.4 mL) was cooled to –20 °C and treated with ZnBr₂·2 H₂O (237 mg, 1.05 mmol, 4.0 equiv) and then with pTsCl (248 mg, 1.3 mmol, 5.0 equiv) in anhyd pyridine (1 mL). The mixture was stirred at –20 °C for 1 h. The reaction was carried out twice in separate flasks. The reaction mixtures were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel, EtOAc); yield: 115 mg (31%); colorless solid.

IR (ATR): 3284, 2924, 1731, 1598, 1354, 1173, 993, 928, 812, 691, 660, 551 cm^–1.

¹H NMR (400 MHz, DMSO-d ₆): δ = 7.79–7.71 (m, 4 H, ArH), 7.46 (ddd, J ₁ = 10.0 Hz, J ₂ = 8.6 Hz, J ₃ = 0.6 Hz, 4 H, ArH), 5.54 (d, J = 3.2 Hz, 1 H, OH), 5.49 (d, J = 6.4 Hz, 1 H, OH), 5.33 (d, J = 5.4 Hz, 1 H, OH), 5.23 (d, J = 5.8 Hz, 1 H, OH), 5.03 (d, J = 5.1 Hz, 1 H, OH), 4.93 (d, J = 3.7 Hz, 1 H, α-H_1′), 4.29–4.23 (m, 2 H), 4.22–4.19 (m, 1 H), 4.14–4.06 (m, 4 H), 3.51–3.56 (m, 1 H), 3.48 (t, J = 2.5 Hz, 2 H), 3.37 (d, J = 3.2 Hz, 1 H), 3.26–3.30 (m, 1 H), 3.21–3.26 (m, 1 H), 3.13–3.18 (m, 1 H), 3.08 (dd, J ₁ = 9.7 Hz, J ₂ = 5.7 Hz, 1 H), 2.96 (dd, J ₁ = 5.3 Hz, J ₂ = 1.1 Hz, 1 H), 2.41 (s, 6 H, ArCH ₃).

¹³C NMR (125 MHz, DMSO-d ₆): δ = 145.0, 144.9, 132.4, 132.3 (4 s, Ar), 130.1, 127.7, 127.5 (3 d, Ar), 100.7 (d), 100.4 (d), 79.5 (d), 78.9 (d), 77.6 (s), 75.8, 72.8, 72.4 (3 d), 71.9 (t, CH₂OTs), 71.5 (d), 70.4 (t, CH₂OTs), 69.3, 68.8 (2 d), 55.1 (t, CH₂C≡CH), 21.2 (q, ArCH₃).

HRMS (ESI): m/z calcd for C₂₉H₃₇O₁₅S₂ [M + H]⁺: 689.15684; found: 689.15570.

(2S,3S,4S,5R,6S)-2-({[4-(Di-tert-butylfluorsilyl)phenyl]thio}methyl)-6-{[(2S,3S,4R,5R,6R)-2-({[4-(di-tert-butylfluorsilyl)phenyl]thio}methyl)-4,5-dihydroxy-6-(prop-2-yn-1-yloxy)tetra­hydro-2H-pyran-3-yl]oxy)}tetrahydro-2H-pyran-3,4,5-triol (11b)

A solution of 4 (144.1 mg, 0.53 mmol, 2.4 equiv) in anhyd DMSO (3 mL) was treated with tBuOK (59.8 mg, 0.53 mmol, 2.4 equiv). The mixture was stirred at 50 °C for 30 min. After the addition of 10b (152.9 mg, 0.22 mmol, 1 equiv) in anhyd DMSO (1 mL), the mixture was stirred at 50 °C for 2 d. Cooling to rt was followed by addition of excess aq 1 M HCl. The mixture was dissolved in Et₂O and washed with aq 1 M HCl (3 × 20 mL) and H₂O (3 × 20 mL). After drying (MgSO₄), the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with cyclohexane/EtOAc (3:1) and ending with EtOAc­/MeOH (10:1); yield: 109 mg (55%); colorless solid.

IR (ATR): 3298, 2933, 2859, 1732, 1582, 1471, 1365, 1245, 1062, 1012, 824, 812, 741, 646, 601, 504, 430 cm^–1.

¹H NMR (600 MHz, DMSO-d ₆): δ = 7.44–7.39 (m, 4 H, ArH), 7.36 (d, J = 8.1 Hz, 2 H, ArH), 7.26 (d, J = 8.1 Hz, 2 H, ArH), 5.72 (d, J = 2.6 Hz, 1 H, OH), 5.64 (d, J = 6.6 Hz, 1 H, OH), 5.34–5.29 (m, 2 H, 2 × OH), 5.13 (d, J = 3.7 Hz, 1 H, α-H_1′), 5.06 (d, J = 5.1 Hz, 1 H, OH), 4.93 (td, J ₁ = 6.5 Hz, J ₂ = 3.9 Hz, 1 H), 4.29 (d, J = 7.7 Hz, 1 H, β-H-1), 4.11 (d, J = 2.6 Hz, 1 H), 3.99 (d, J = 13.6 Hz, 1 H, H-7b), 3.80–3.77 (m, 1 H, H-3), 3.53–3.44 (m, 2 H), 3.43–3.34 (m, 7 H), 3.23–3.18 (m, 1 H), 3.14–3.08 (m, 1 H), 3.08–2.98 (m, 2 H), 0.97 [d, J = 8.1 Hz, 36 H, 4 × C(CH₃)₃].

¹³C NMR (150 MHz, DMSO-d ₆): δ = 140.0, 139.8 (2 s, Ar), 133.9 (d, J = 4.1 Hz, Ar), 133.8 (d, J = 4.1 Hz, Ar), 128.5 (s, J = 13.9 Hz, Ar), 128.3 (s, J = 13.9 Hz, Ar), 126.4 (d, Ar), 125.8 (d, Ar), 101.2 (d), 100.5 (d), 82.9 (d), 79.3 (s), 77.5 (s), 76.0, 74.2 (2 d), 72.8 (d, J = 7.1 Hz), 72.6, 72.3 (2 d), 72.01 (d, J = 3.4 Hz), 68.8 (d), 58.3 (d), 54.7 (t), 31.4, 28.0 (2 t), 27.0 [q, C(CH₃)₃], 19.8, 19.7 [2 s, J = 4.7 Hz, C(CH₃)₃].

¹⁹F NMR (565 MHz, CDCl₃): δ = –187.5, –187.5 (2 d, J = 297.8 Hz).

²⁹Si NMR (119 MHz, CDCl₃): δ = 15.5, 13.0 (2 d, J = 298.1 Hz).

HRMS (ESI): m/z calcd for C₄₄H₆₇F₂O₁₁S₂Si₂ [M + HCOO]^–: 929.36259; found: 929.36097.

((2R,3R,4S,5R,6S)-6-{[(2R,3S,4R,5R,6R)-6-Azido-4,5-dihydroxy-2-[(tosyloxy)methyl]tetrahydro-2H-pyran-3-yl]oxy}-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-Methylbenzolsulfonate (13a)

A solution of 12a (100 mg, 0.27 mmol, 1.0 equiv) in anhyd pyridine (2.4 mL) was cooled to –20 °C and treated with ZnBr₂·2 H₂O (243 mg, 1.08 mmol, 4.0 equiv) and then with pTsCl (257 mg, 1.35 mmol, 5.0 equiv) in anhyd pyridine (1 mL). The mixture was stirred at –20 °C for 15 min. The reaction was carried out twice in separate flasks. The reaction mixtures were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with EtOAc/cyclohexane (30:1) and ending with EtOAc/MeOH (10:1); yield: 160 mg (44%); colorless solid.

IR (ATR): 3369, 2912, 2116, 1728, 1598, 1451, 1352, 1255, 1173, 1060, 971, 811, 769, 689, 662, 550 cm^–1.

¹H NMR (500 MHz, DMSO-d ₆): δ = 7.83–7.76 (m, 4 H, ArH), 7.49–7.45 (m, 4 H, ArH), 5.82 (d, J = 5.6 Hz, 1 H), 5.16 (d, J = 3.8 Hz, 1 H), 4.96 (d, J = 4.7 Hz, 1 H), 4.82 (d, J = 4.7 Hz, 1 H), 4.59–4.55 (m, 2 H), 4.46 (d, J = 9.9 Hz, 1 H), 4.20–4.10 (m, 3 H), 3.91 (t, J = 9.2 Hz, 1 H), 3.76–3.72 (m, 2 H), 3.30–3.23 (m, 3 H), 3.04–3.01 (m, 1 H), 2.42 (d, J = 1.5 Hz, 6 H, 2 × ArCH ₃). OH groups were not detected.

¹³C NMR (125 MHz, DMSO-d ₆): δ = 145.2, 144.9, 132.3, 131.8 (4 s, Ar), 130.3, 130.1, 127.9, 127.7 (4 d, Ar), 102.8 (d, CHO), 89.2 (d, CHN₃), 78.5, 74.0, 73.3, 72.6, 72.4, 72.2 (6 d, CH), 69.9 (t, CH₂OTs) 69.8 (d, CH), 69.2 (t, CH₂OTs), 68.0 (d, CH), 21.2 (q, ArCH₃).

HRMS (ESI): m/z calcd for C₂₆H₃₃N₃O₁₄S₂Na [M + Na]⁺: 698.12962; found: 698.12936.

(2R,3R,4S,5R,6S)-2-{[(2S,3S,4R,5R,6R)-6-Azido-2-({[4-(di-tert-butylfluorosilyl)phenyl]thio}methyl)-4,5-dihydroxytetrahydro-2H-pyran-3-yl]oxy}-6-({[4-(di-tert-butylfluorsilyl)phenyl]thio}methyl)tetrahydro-2H-pyran-3,4,5-triol (14a)

A solution of 4 (136 mg, 0.5 mmol, 2.4 equiv) in anhyd DMSO (3 mL) was treated with tBuOK (57 mg, 0.5 mmol, 2.4 equiv). The mixture was stirred at 50 °C for 30 min. After the addition of 13a (142 mg, 0.21 mmol, 1 equiv) in anhyd DMSO (1 mL), the mixture was stirred at 50 °C for 48 h. Cooling to rt was followed by addition of excess aq 1 M HCl. The mixture was dissolved in Et₂O and washed with aq 1 M HCl (3 × 20 mL) and H₂O (3 × 20 mL). After drying (MgSO₄), the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with cyclohexane/EtOAc (3:1) and ending with EtOAc; yield: 61 mg (33%); colorless solid.

IR (ATR): 3371, 2935, 2860, 2117, 1582, 1470, 1366, 1249, 1054, 936, 816, 741, 646, 600, 505 cm^–1.

¹H NMR (600 MHz, DMSO-d ₆): δ = 7.49–7.44 (m, 4 H, ArH), 7.39–7.33 (m, 4 H, ArH), 5.75 (d, J = 5.6 Hz, 1 H), 5.33 (d, J = 5 Hz, 1 H), 4.93 (d, J = 5.6 Hz, 1 H), 4.88 (d, J = 5 Hz, 1 H), 4.70 (d, J = 1.9 Hz, 1 H), 4.59 (d, J = 8.7 Hz, 1 H), 4.36 (d, J = 7.8 Hz, 1 H), 4.03 (q, J = 7.1 Hz, 1 H), 3.80–3.71 (m, 3 H), 3.65 (t, J = 6.7 Hz, 1 H), 3.45–3.41 (m, 3 H), 3.23–3.11 (m, 3 H), 1.01–1.00 [m, 36 H, 4 × C(CH₃)₃].

¹³C NMR (150 MHz, DMSO-d ₆): δ = 139.5, 139.0 (2 s, Ar), 134.1 (d, J = 4.1 Hz, Ar), 134.0 (d, J = 3.9 Hz, Ar), 128.8 (s, J = 13.8 Hz, Ar), 128.3 (s, J = 13.8 Hz, Ar), 126.2, 125.9 (2 d, Ar), 103.2 (d, CHO), 89.4 (d, CHN₃), 81.4, 75.4, 74.0, 73.3 (4 d, CH), 73.1 (d, J = 7.4 Hz, CH), 70.1, 69.2 (2 d, CH), 32.4 (t, CH₂S), 32.2 (t, CH₂S), 28.0 [q, J = 6.1 Hz, C(CH₃)₃], 27.0 [q, C(CH₃)₃], 19.8 [s, C(CH₃)₃], 19.7 [s, C(CH₃)₃].

¹⁹F NMR (565 MHz, DMSO-d ₆): δ = –187.4 (d, J = 297.5 Hz).

²⁹SiNMR (119 MHz, DMSO-d ₆): δ = 15.6 (d, J = 297.5 Hz).

HRMS (ESI): m/z calcd for C₄₀H₆₄F₂N₃O₈S₂Si₂ [M + H]⁺: 872.36359; found: 872.36441.

((2R,3R,4S,5R,6S)-6-{[(2R,3S,4R,5R,6R)-4,5-Dihydroxy-6-(prop-2-yn-1-yloxy)-2-[(tosyloxy)methyl]-tetrahydro-2H-pyran-3-yl]oxy}-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 4-Methylbenzolsulfonate (13b)

A solution of 12b (100 mg, 0.26 mmol, 1.0 equiv) in anhyd pyridine (2.3 mL) was cooled to –20 °C and treated with ZnBr₂·2 H₂O (237 mg, 1.05 mmol, 4.0 equiv) and then with pTsCl (251 mg, 1.3 mmol, 5.0 equiv) in anhyd pyridine (1 mL). The mixture was stirred at –20 °C for 90 min. The reaction was carried out twice in separate flasks. The reaction mixtures were combined, the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel, EtOAc); yield: 130 mg (36%); colorless solid.

IR (ATR): 3334, 2912, 1728, 1598, 1451, 1352, 1173, 1122, 1049, 1019, 971, 931, 836, 813, 769, 691, 661, 551 cm^–1.

¹H NMR (400 MHz, DMSO-d ₆): δ = 7.84–7.77 (m, 4 H, ArH), 7.50–7.46 (m, 4 H, ArH), 5.46 (d, J = 5.4 Hz, 1 H), 5.16 (d, J = 4.1 Hz, 1 H), 4.96 (d, J = 5 Hz, 1 H), 4.82 (d, J = 4.9 Hz, 1 H), 4.54 (d, J = 2.1 Hz, 1 H), 4.47 (d, J = 9.3 Hz, 1 H), 4.31 (d, J = 7.8 Hz, 1 H), 4.23–4.07 (m, 5 H), 4.02 (t, J = 6.8 Hz, 1 H), 3.91 (dd, J ₁ = 9.9 Hz, J ₂ = 8.5 Hz, 1 H), 3.78–3.76 (m, 1 H), 3.59–3.51 (m, 3 H), 3.27–3.24 (m, 3 H), 3.04–2.99 (m, 1 H), 2.43 (s, 6 H, 2 × ArCH ₃).

¹³C NMR (125 MHz, DMSO-d ₆): δ = 145.1, 144.8, 132.5, 131.8 (4 s, Ar), 130.3, 130.1, 127.9, 127.7 (4 d, Ar), 102.7 (d, CHO), 100.3 (d, CHOCH₂), 79.6 (s, C≡CH), 77.6 (d, C≡CH), 74.0, 72.6, 72.5, 72.2, 71.4, 69.8, 69.4, 68.0 (8 d), 62.3 (t, CH₂OTs), 55.0 (t, CHOCH₂), 21.2 (q, ArCH₃).

HRMS (ESI): m/z calcd for C₂₉H₃₇O₁₅S₂ [M + H]⁺: 689.15684; found: 689.15712.

(2S,3R,4S,5R,6R)-2-({[4-(Di-tert-butylfluorsilyl)phenyl]thio}methyl)-6-{[(2S,3S,4R,5R,6R)-2-({[4-(di-tert-butylfluorsilyl)phenyl]-thio}methyl)-4,5-dihydroxy-6-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran-3-yl]oxy}tetrahydro-2H-pyran-3,4,5-triol (14b)

A solution of 4 (94 mg, 0.35 mmol, 2.4 equiv) in anhyd DMSO (1.5 mL) was treated with tBuOK (39 mg, 0.35 mmol, 2.4 equiv). The mixture was stirred at 50 °C for 30 min. After the addition of 13b (100 mg, 0.15 mmol, 1 equiv) in anhyd DMSO (1 mL), the mixture was stirred at 50 °C for 2 d. Cooling to rt was followed by addition of excess aq 1 M HCl. The mixture was dissolved in Et₂O and washed with aq 1 M HCl (3 × 20 mL) and H₂O (3 × 20 mL). After drying (MgSO₄), the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with cyclohexane/EtOAc (3:1) and ending with EtOAc/MeOH (10:1); yield: 47 mg (36%); colorless solid.

IR (ATR): 3396, 2934, 2859, 1715, 1582, 1471, 1365, 1074, 825, 812, 741, 646, 601, 505, 430 cm^–1.

¹H NMR (600 MHz, DMSO-d ₆): δ = 7.46 (dd, J ₁ = 19.8 Hz, J ₂ = 8.1 Hz, 4 H ArH), 7.38 (d, J = 8.2 Hz, 2 H, ArH), 7.34 (d, J = 8.2 Hz, 2 H, ArH), 5.38 (d, J = 5.3 Hz, 1 H, OH), 5.30 (d, J = 4.8 Hz, 1 H, OH), 4.91 (d, J = 5.4 Hz, 1 H, OH), 4.86 (d, J = 4.9 Hz, 1 H, OH), 4.64 (d, J = 1.8 Hz, 1 H, OH), 4.37–4.32 (m, 2 H), 4.19 (dd, J ₁ = 15.6 Hz, J ₂ = 2.4 Hz, 1 H), 4.11–4.04 (m, 2 H), 3.77–3.70 (m, 2 H), 3.67–3.64 (m, 1 H), 3.59–3.54 (m, 1 H), 3.43–3.37 (m, 4 H), 3.26–3.21 (m, 1 H), 3.16–3.08 (m, 3 H), 1.00 [d, J = 5.0 Hz, 36 H, 4 × C(CH₃)₃].

¹³C NMR (150 MHz, DMSO-d ₆): δ = 140.2, 139.6 (2 s, Ar), 134.6 (d, J = 4.4 Hz, Ar), 134.4 (d, J = 4.4 Hz, Ar), 129.2 (s, J = 14.3 Hz, Ar), 128.7 (s, J = 14.3 Hz, Ar), 126.7, 126.4 (2 d, Ar), 103.6 (d), 100.9 (d), 82.2 (d), 79.9 (s), 77.9, 74.6, 74.4, 73.7 (4 d), 73.5 (d, J = 2.2 Hz), 70.5 (d), 69.7 (d), 67.7 (d, J = 12.1 Hz), 55.3 (t), 33.0, 32.8 (2 t), 27.5 [q, C(CH₃)₃], 20.2 [s, J = 12.1 Hz, C(CH₃)₃].

¹⁹F NMR (565 MHz, CDCl₃): δ = –187.4, –187.4 (2 d, J = 297.8 Hz).

²⁹Si NMR (119 MHz, CDCl₃): δ = 15.5, 13.6 (2 d, J = 297.6 Hz).

HRMS (ESI): m/z calcd for C₄₃H₆₆F₂O₉S₂Si₂ [M + Na]⁺: 907.35471; found: 907.35541.

((2R,3S,4R,5R,6R)-6-Azido-3-{[(4aR,6S,7R,8R)-7,8-dihydroxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy}-4,5-dihydroxytetrahydro-2H-pyran-2-yl)methyl 4-Methylbenzensulfonate (16) and (4aR,6S,7R,8R)-6-{[(2R,3S,4R,5R,6R)-6-Azido-4,5-dihydroxy-2-[(tosyloxy)methyl]tetrahydro-2H-pyran-3-yl]oxy}-7-hydroxy-2-phenylhexahydropyran[3,2-d][1,3]dioxin-8-yl 4-Methylbenzenesulfonate (17)

A solution of 15 (100 mg, 0.22 mmol, 1.0 equiv) in anhyd pyridine (2 mL) was cooled to –20 °C and treated with ZnBr₂·2 H₂O (198 mg, 0.88 mmol, 4.0 equiv) and then with pTsCl (209 mg, 1.1 mmol, 5.0 equiv) in anhyd pyridine (1 mL). The mixture was stirred at –20 °C for 30 min. The solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with EtOAc/cyclohexane (1:1, + 1% Et₃N) and ending with EtOAc/MeOH (30:1, + 1% Et₃N).

16

Yield: 66 mg (49%); colorless solid.

IR (ATR): 3334, 2911, 2113, 1598, 1359, 1248, 1174, 1095, 1033, 994, 964, 903, 839, 810, 774, 741, 698, 670, 597, 554, 520, 481 cm^–1.

¹H NMR (600 MHz, DMSO-d ₆): δ = 7.76 (d, J = 8.1 Hz, 2 H, ArH), 7.44 (dd, J ₁ = 6.1 Hz, J ₂ = 2.4 Hz, 2 H, ArH), 7.41–7.35 (m, 5 H, ArH), 5.74 (d, J = 5.6 Hz, 1 H, OH), 5.56 (s, 1 H), 5.19 (d, J = 4.1 Hz, 1 H, OH), 5.06–4.99 (m, 2 H, OH), 4.63–4.56 (m, 2 H), 4.33 (d, J = 7.4 Hz, 1 H), 4.13 (dd, J ₁ = 11.0 Hz, J ₂ = 7.2 Hz, 1 H), 4.09–4.05 (m, 2 H), 3.96 (d, J = 12.2 Hz, 1 H), 3.79 (t, J = 8.3 Hz, 1 H), 3.58 (s, 1 H), 3.48–3.39 (m, 3 H), 3.36 (d, J = 9.5 Hz, 1 H), 3.03 (td, J ₁ = 8.6 Hz, J ₂ = 5.8 Hz, 1 H), 2.38 (s, 3 H, ArCH ₃).

¹³C NMR (150 MHz, DMSO-d ₆): δ = 145.3 (s, Ar), 139.0 (s, Ar), 132.7 (s, Ar), 130.5, 129.2 (2 d, Ar), 128.4 (d, Ar), 128.1, 126.7 (2 d, Ar), 102.8 (d), 100.2 (d), 89.7 (d), 77.5, 76.1, 74.6 73.9, 73.3, 72.0, 70.0 (7 d), 69.8, 68.9 (2 t), 66.8 (d), 21.6 ArCH₃).

HRMS (ESI): m/z calcd for C₂₆H₃₂N₃O₁₂S [M + H]⁺: 610.17012; found: 610.17125.

17

Yield: 52 mg (31%); colorless solid.

IR (ATR): 3486, 3037, 2875, 2116, 1729, 1598, 1357, 1246, 1173, 1093, 1043, 963, 905, 868, 812, 697, 669, 552 cm^–1.

¹H NMR (600 MHz, DMSO-d ₆): δ = 7.82 (d, J = 8.2 Hz, 2 H, ArH), 7.74 (d, J = 8.2 Hz, 2 H, ArH), 7.42 (d, J = 8.2 Hz, 2 H, ArH), 7.39–7.35 (m, 5 H, ArH), 7.29–7.26 (m, 2 H, ArH), 5.76 (d, J = 5.5 Hz, 1 H, OH), 5.61 (d, J = 5.5 Hz, 1 H, OH), 5.35 (s, 1 H), 5.04 (d, J = 3.1 Hz, 1 H, OH), 4.62–4.51 (m, 4 H), 4.48 (d, J = 7.6 Hz, 1 H), 4.25 (d, J = 3.4 Hz, 1 H), 4.03–4.09 (m, 2 H), 3.99–3.95 (m, 1 H), 3.78–3.73 (m, 1 H), 3.70 (s, 1 H), 3.54 (ddd, J ₁ = 9.5 Hz, J ₂ = 7.9 Hz, J ₃ = 5.5 Hz, 1 H), 3.43–3.36 (m, 2 H,), 3.01 (td, J ₁ = 8.5 Hz, J ₂ = 5.8 Hz, 1 H), 2.38 (d, J = 3.7 Hz, 6 H, 2 × ArCH ₃).

¹³C NMR (150 MHz, DMSO-d ₆): δ = 145.1 (s, Ar), 144.9 (s, Ar), 138.1 (s, Ar), 134.0 (s, Ar), 132.3 (s, Ar), 130.2, 130.0, 129.1, 128.2 (4 d, Ar), 127.8 (d, J = 13.6 Hz, Ar), 126.2 (d, Ar), 102.8 (d), 100.2 (d), 89.7 (d), 77.5, 76.1, 74.6 73.9, 73.3, 72.0, 70.0 (7 d), 69.8, 68.9 (t), 66.8 (d), 21.6 (q, ArCH₃).

LRMS (ESI): m/z calcd for C₂₆H₃₁N₃O₁₂SNa [M + Na]⁺: 786.16; found: 786.32.

X-ray Crystal Data[11]

Intensity data for the colorless crystal of compound 17 were collected on a D8 Venture Bruker Diffractometer, SC-XRD using Cu-Kα radiation at 173(2) K. The molecular structure was solved with direct methods using SHELXS-2014/7 or SHELXT-2014/7 and refinements were carried out against F2 by using SHELXL-2014/7[27] or OLEX2.[28] The data obtained by the measurement were treated in the refinement procedure as a 2-component twin. Applying the TwinRotMat option in the program PLATON[29] revealed a twin law (BASF 0. 0.13258).

(4aR,6S,7R,8R)-6-{[(2S,3S,4R,5R,6R)-6-Azido-2-({[4-(di-tert-butylfluorsilyl)phenyl]thio}methyl)-4,5-dihydroxytetrahydro-2H-pyran-3-yl]oxy}-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7,8-diol (18)

A solution of 4 (110 mg, 0.41 mmol, 1.2 equiv) in anhyd DMSO (3 mL) was treated with tBuOK (45.8 mg, 0.41 mmol, 1.2 equiv). The mixture was stirred at 50 °C for 30 min. After the addition of 16 (207 mg, 0.34 mmol, 1 equiv) in anhyd DMSO (1 mL), the mixture was stirred at 50 °C for 2 d. Cooling to rt was followed by addition of excess aq 1 M HCl. The mixture was dissolved in Et₂O and washed with aq 1 M HCl (3 × 20 mL) and H₂O (3 × 20 mL). After drying (MgSO₄), the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with cyclohexane/EtOAc (2:1) and ending with EtOAc; yield: 146 mg (61%); colorless solid.

IR (ATR): 3385, 2934, 2933, 2859, 2115, 1733, 1582, 1471, 1365, 1245, 1163, 1027, 901, 812, 740, 699, 647, 601, 505, 431 cm^–1.

¹H NMR (600 MHz, DMSO-d ₆): δ = 7.47 (d, J = 7.7 Hz, 4 H, ArH), 7.42–7.35 (m, 5 H, ArH), 5.70 (d, J = 5.5 Hz, 1 H, OH), 5.58 (s, 1 H), 5.47 (d, J = 4.4 Hz, 1 H, OH), 5.13–5.07 (m, 1 H, OH), 4.83–4.77 (m, 1 H, OH), 4.64 (d, J = 8.4 Hz, 1 H), 4.50–4.46 (m, 1 H), 4.11 (d, J = 2.6 Hz, 2 H), 4.00 (d, J = 12.1 Hz, 1 H), 3.85–3.81 (m, 1 H), 3.75 (br s, 1 H), 3.65 (s, 1 H), 3.54–3.47 (m, 2 H), 3.45–3.43 (m, 2 H), 3.18–3.08 (m, 2 H), 1.01 [s, 18 H, 2 × C(CH₃)₃].

¹³C NMR (150 MHz, DMSO-d ₆): δ = 139.8, 138.9, 135.3 (3 s, Ar), 134.4 (d, J = 4.4 Hz, Ar), 129.1, 128.3, 126.6, 126.2 (4 d, Ar), 103.7 (d, C-1′), 100.1 (d), 89.9 (d), 82.3, 76.1, 75.8, 74.5, 73.7, 72.2, 70.3 (7 d), 68.8 (t), 66.8 (d), 32.7 (t), 28.4, 27.4 [2 q, C(CH₃)₃)], 20.2 [d, J = 12.1 Hz, C(CH₃)₃].

¹⁹F NMR (565 MHz, CDCl₃): δ = –187.4 (d, J = 296.5 Hz).

²⁹Si NMR (119 MHz, CDCl₃): δ = 15.6 (d, J = 297.1 Hz).

HRMS (ESI): m/z calcd for C₃₄H₄₇FN₃O₁₁SSi [M + HCOO]^–: 752.26791; found: 752.26732.

(2S,3R,4S,5R,6R)-2-{[(2S,3S,4R,5R,6R)-6-Azido-2-({[4-(di-tert-butylfluorsilyl)phenyl]thio}methyl)-4,5-dihydroxytetrahydro-2H-pyran-3-yl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (19)

A mixture of 18 (124 mg, 0.18 mmol, 1.0 equiv) and 80% aq AcOH (4 mL) was stirred at 70 °C for 4 h. After cooling to rt, the mixture was extracted with toluene (3 × 20 mL). After drying (MgSO₄), the solvent was removed under reduced pressure, and the crude product was purified by column chromatography (silica gel) using a gradient starting with EtOAc and ending with EtOAc/MeOH (10:1); yield: 71 mg (64%); colorless solid.

IR (ATR): 3359, 2933, 2859, 2121, 1583, 1366, 1245, 1172, 1068, 1034, 878, 814, 778, 741, 700, 645, 599, 503, 437 cm^–1.

¹H NMR (600 MHz, DMSO-d ₆): δ = 7.53–7.30 (m, 4 H, Ar), 5.69 (d, J = 5.5 Hz, 1 H, OH), 5.33–5.25 (m, 1 H, OH), 4.88–4.82 (m, 2 H), 4.67 (t, J = 5.0 Hz, 1 H, OH), 4.62 (d, J = 8.4 Hz, 1 H), 4.55 (d, J = 4.8 Hz, 1 H), 4.44 (br. s., 1 H, OH), 4.28 (d, J = 7.7 Hz, 1 H), 3.82–3.77 (m, 1 H), 3.73–3.68 (m, 1 H), 3.63 (br s, 1 H), 3.57–3.45 (m, 3 H), 3.40–3.34 (m, 4H), 3.15–3.06 (m, 2 H), 1.02–0.95 [m, 18 H, 2 × C(CH₃)₃].

¹³C NMR (150 MHz, DMSO-d ₆): δ = 139.5 (s, Ar), 134.1 (d, J = 4.4 Hz, Ar), 128.3 (s, J = 13.2 Hz, Ar), 126.0 (d, Ar), 104.3 (d), 89.5 (d), 83.1, 75.8, 75.4, 74.6, 73.5, 73.1, 70.6, 68.3 (8 d), 60.5 (t), 32.4 (t), 28.1, 27.2 [2 q, C(CH₃)₃], 19.9 [s, J = 13.2 Hz, C(CH₃)₃].

¹⁹F NMR (565 MHz, CDCl₃): δ = –187.4 (d, J = 297.2 Hz).

²⁹Si NMR (119 MHz, CDCl₃): δ = 15.6 (d, J = 297.3 Hz).

HRMS (ESI): m/z calcd for C₂₆H₄₂FN₃O₉SSiNa [M + Na]⁺: 642.22873; found: 642.22877.

• References

• 1 Shukla AK, Kumar U. J. Med. Phys. 2006; 31: 13
• 2a Ametamey SM, Honer M, Schubiger PA. Chem. Rev. 2008; 108: 1501
• 2b Schirrmacher R, Wängler C, Schirrmacher E. Mini-Rev. Org. Chem. 2007; 4: 317
• 2c Miller PW, Long NJ, Vilar R, Gee AD. Angew. Chem. Int. Ed. 2008; 47: 8998
• 3a Ying L. Sci. China Chem. 2013; 56: 1682
• 3b Gao Z, Gouverneur V, Davis BG. J. Am. Chem. Soc. 2013; 135: 13612
• 3c Brust P, Van den Hoff J, Steinbach J. Neurosci. Bull. 2014; 30: 777
• 3d Liang SH, Vasdev N. Angew. Chem. Int. Ed. 2014; 53: 2
• 3e Fehler SK, Maschauer S, Höfling SB, Bartuschat AL, Tschammer N, Hübner H, Gmeiner P, Prante O, Heinrich MR. Chem. Eur. J. 2014; 20: 370
• 3f Van der Born D, Pees A, Poot AJ, Orru RV. A, Windhorst AD, Vugts DJ. Chem. Soc. Rev. 2017; 46: 4709
• 3g Jakobsson JE, Grønnevik G, Riss PJ. Chem. Commun. 2017; 53: 12906
• 4 Gens TA, Wethongton JA, Brosi AR. J. Phys. Chem. 1958; 62: 1593
• 5a Smith GE, Sladen HL, Biagini SC. G, Blower PJ. Dalton Trans. 2011; 40: 6196
• 5b Chansaenpak K, Vabre B, Gabbai FP. Chem. Soc. Rev. 2016; 45: 954
• 5c Gauthier VB, Bailey JJ, Liu Z, Wängler B, Wängler C, Jurkschat K, Perrin DM, Schirrmacher R. Bioconjugate Chem. 2016; 27: 267
• 5d Wilson TC, Cailly T, Gouverneur V. Chem. Soc. Rev. 2018; 47: 6990
• 5e Schirrmacher R, Bernard-Gauthier V, Schirrmacher E, Bailey JJ, Jurkschat K, Wängler C, Wängler B. In Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals . Haufe G. Elsevier; Amsterdam: 2019. Chap. 15
• 6 Mu LJ, Hohne A, Schubiger RA, Ametamey SM, Graham K, Cyr JE, Dinkelborg L, Stellfeld T, Srinivasan A, Voigtmann U, Klar U. Angew. Chem. Int. Ed. 2008; 47: 4922
• 7a Schirrmacher R, Bradtmöller G, Schirrmacher E, Thews O, Tillmanns J, Siessmeier T, Buchholz HG, Bartenstein P, Wängler B, Niemeyer CM, Jurkschat K. Angew. Chem. Int. Ed. 2006; 45: 6047
• 7b Tietze LF, Schmuck K. Synlett 2011; 1697
• 7c Joyard Y, Azzouz R, Bischoff L, Papamicaël C, Labar D, Bol A, Bol V, Vera P, Grégoire V, Levacher V, Bohn P. Bioorg. Med. Chem. 2013; 21: 3680
• 7d Jana S, Al-huniti MH, Yang BY, Lu S, Pike VW, Lepore SD. J. Org. Chem. 2017; 82: 2329
• 7e Tisseraud M, Schulz J, Vimont D, Berlande M, Fernandez P, Hermange P, Fouquet E. Chem. Commun. 2018; 54: 5098
• 7f Boutureira O, Bernardes GJ. L, D’Hooge F, Davis BG. Chem. Commun. 2011; 47: 10010
• 8 Iovkova L, Wängler B, Schirrmacher E, Schirrmacher R, Quandt G, Boening G, Schürmann M, Jurkschat K. Chem. Eur. J. 2009; 15: 2140
• 9 Yamamura H, Kawasaki J, Saito H, Araki S, Kawai M. Chem. Lett. 2001; 30: 706
• 10 Ying L, Gervay-Hague J. Carbohydr. Res. 2003; 338: 835
• 11 CCDC 1866515 contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.
• 12 Lai Y.-C, Luo C.-H, Chou H.-C, Yang C.-J, Lu L, Chen C.-S. Tetrahedron Lett. 2016; 57: 2474
• 13 Bernardes GJ. L, Marston JP, Batsanov AS, Howard JA. K, Davis BG. Chem. Commun. 2007; 3145
• 14 Jha AK, Jain N. Tetrahedron Lett. 2013; 54: 4738
• 15 Liu F, Tang P, Ding R, Liao L, Wang L, Wang M, Wang J. Dalton Trans. 2017; 46: 7515
• 16 Tong Z, Pu S, Xiao Q, Liu G, Cui S. Tetrahedron Lett. 2013; 54: 474
• 17 Mauceri A, Borocci S, Galantini L, Giansanti L, Mancini G, Martino A, Manni LS, Sperduto C. Langmuir 2014; 30: 11301
• 18 Chatterjee D, Paul A, Yadav R, Yadav S. RSC Adv. 2015; 5: 29669
• 19 Yuan X, Cheng S, Shi Y, Xue W. Synthesis 2014; 46: 331
• 20 Okafor IS, Wang G. Carbohydr. Res. 2017; 451: 81
• 21 Eisink NN. H. M, Lohse J, Witte MD, Minnaard AJ. Org. Biomol. Chem. 2016; 14: 4859
• 22 Ma D.-L, Shum TY.-T, Zhang F, Che C.-M, Yang M. Chem. Commun. 2005; 4675
• 23 Maki T, Ishida K. J. Org. Chem. 2007; 72: 6427
• 24 Sun B, Jiang H. Tetrahedron Lett. 2012; 53: 5711
• 25 Calatrava-Pérez E, Bright SA, Achermann S, Moylan C, Senge MO, Veale EB, Williams DC, Gunnlaugsson T, Scanlan EM. Chem. Commun. 2016; 52: 13086
• 26 Abellán Flos M, García Moreno MI, Ortiz Mellet C, García Fernández JM, Nierengarten J.-F, Vincent SP. Chem. Eur. J. 2016; 22: 11450
• 27 Sheldrick GM. Acta Crystallogr., Sect. C 2015; 71: 3
• 28 Dolomanov OV, Bourhis LJ, Gildea RJ, Howard JA. K, Puschmann H. J. Appl. Cryst. 2009; 42: 339
• 29 Spek AL. Acta Crystallogr., Sect. D 2009; 65: 148